HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ken Suzawa Selected Research

ErbB Receptors (EGF Receptor)

2/2024Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
4/2019Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
1/2019Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer.
1/2018Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
1/2016Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
3/2015Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ken Suzawa Research Topics

Disease

30Neoplasms (Cancer)
05/2024 - 03/2014
22Lung Neoplasms (Lung Cancer)
04/2024 - 03/2015
18Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2024 - 01/2014
7Neoplasm Metastasis (Metastasis)
02/2024 - 01/2018
4Sarcoma (Soft Tissue Sarcoma)
12/2023 - 01/2021
4Breast Neoplasms (Breast Cancer)
11/2021 - 01/2017
3Bronchiolitis Obliterans Syndrome
11/2023 - 02/2022
2Radiation Pneumonitis
03/2024 - 08/2020
2Adenocarcinoma of Lung
02/2024 - 01/2020
2Primary Graft Dysfunction
02/2024 - 10/2018
2Lymphatic Metastasis
10/2023 - 01/2022
2Pulmonary Fibrosis (Fibrosing Alveolitis)
04/2023 - 01/2021
2Ischemia
11/2022 - 10/2021
2Interstitial Lung Diseases (Interstitial Lung Disease)
11/2022 - 01/2021
2Lung Injury
10/2021 - 01/2021
1Critical Illness (Critically Ill)
05/2024
1Postoperative Hemorrhage
04/2024
1Acute Lung Injury
02/2024
1Sepsis (Septicemia)
02/2024
1Carcinoma (Carcinomatosis)
01/2024
1Leiomyosarcoma
12/2023
1Adenocarcinoma
10/2023
1Hemorrhage
01/2023
1Melanoma (Melanoma, Malignant)
09/2022
1Reperfusion Injury
10/2021
1Castleman Disease (Castleman's Disease)
09/2021
1Fistula
02/2021
1Fibrosis (Cirrhosis)
01/2021
1Idiopathic Pulmonary Fibrosis
01/2021
1Inflammation (Inflammations)
01/2021
1Persistent Infection
01/2021
1Pulmonary Aspergillosis
08/2020

Drug/Important Bio-Agent (IBA)

15Tyrosine Kinase InhibitorsIBA
02/2024 - 03/2015
6ErbB Receptors (EGF Receptor)IBA
02/2024 - 03/2015
5Proteins (Proteins, Gene)FDA Link
09/2022 - 12/2016
5human ERBB2 proteinIBA
11/2021 - 01/2017
4Biomarkers (Surrogate Marker)IBA
05/2024 - 10/2018
4AfatinibIBA
05/2018 - 10/2015
3Messenger RNA (mRNA)IBA
01/2022 - 01/2017
2CatecholaminesIBA
04/2024 - 03/2014
2histidine-rich proteinsIBA
02/2024 - 09/2022
2PeriostinIBA
12/2023 - 12/2023
2MicroRNAs (MicroRNA)IBA
04/2023 - 01/2017
2Trastuzumab (Herceptin)FDA Link
11/2021 - 01/2017
2Monoclonal AntibodiesIBA
10/2021 - 09/2021
2Carrier Proteins (Binding Protein)IBA
10/2021 - 12/2016
2Phosphotransferases (Kinase)IBA
12/2020 - 01/2018
2neratinibIBA
03/2020 - 03/2019
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2018 - 12/2016
1Indicators and Reagents (Reagents)IBA
05/2024
1Epinephrine (Adrenaline)FDA LinkGeneric
04/2024
1Adrenergic Agents (Adrenergic Drugs)IBA
04/2024
1EnzymesIBA
04/2024
1Glycoproteins (Glycoprotein)IBA
02/2024
1Plasminogen Activator Inhibitor 1IBA
01/2024
1CrizotinibIBA
01/2024
1RNA (Ribonucleic Acid)IBA
12/2023
1AntibodiesIBA
12/2023
1tranilastIBA
10/2022
1osimertinibIBA
10/2022
1AZD 6244IBA
10/2022
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
09/2022
1Chemotactic FactorsIBA
09/2022
1Blood Proteins (Serum Proteins)IBA
09/2022
1Keratin-19 (Keratin 19)IBA
01/2022
1Nucleic AcidsIBA
01/2022
1Ado-Trastuzumab EmtansineIBA
11/2021
1ChromatinIBA
10/2021
1HMGB1 Protein (HMG1)IBA
10/2021
1HMGB ProteinsIBA
10/2021
1salicylhydroxamic acid (SHAM)IBA
10/2021
1Mitogen-Activated Protein KinasesIBA
10/2021
1ChemokinesIBA
10/2021
1CytokinesIBA
10/2021
1Interleukin-6 (Interleukin 6)IBA
09/2021
1EnbucrilateIBA
02/2021
1EquolIBA
01/2021
1TamoxifenFDA LinkGeneric
01/2021
1indium-bleomycinIBA
01/2021
1Neutralizing AntibodiesIBA
01/2021
1Dihydrotachysterol (AT 10)IBA
01/2021
1IsoflavonesIBA
01/2021
1Hormones (Hormone)IBA
01/2021
1cabozantinibIBA
12/2020
1agerafenibIBA
12/2020
1LY3009120IBA
05/2020
1Dasatinib (BMS 354825)FDA Link
03/2020

Therapy/Procedure

16Therapeutics
02/2024 - 01/2016
9Lung Transplantation
05/2024 - 10/2018
7Chemoradiotherapy
03/2024 - 04/2015
4Adjuvant Chemotherapy
03/2024 - 08/2020
4Metastasectomy
12/2023 - 01/2021
3Operative Time
04/2024 - 01/2023
2Molecular Targeted Therapy
10/2022 - 03/2020
1Drug Therapy (Chemotherapy)
10/2023
1Thoracotomy
10/2023
1Mechanical Ventilators (Ventilator)
11/2022
1Thymectomy
07/2022
1Intravenous Administration
10/2021
1Pneumonectomy (Lung Volume Reduction)
02/2021